Chakraborty R - Search Results

1

Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021.

Efficace F, Cottone F, Sparano F, Caocci G, Vignetti M, Chakraborty R. Efficace F, et al. Among authors: chakraborty r. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):442-459. doi: 10.1016/j.clml.2022.01.009. Epub 2022 Jan 19. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35183476 Review.

2

Life beyond bortezomib: increasing treatment options in refractory myeloma.

Chakraborty R, Gertz MA. Chakraborty R, et al. Leuk Lymphoma. 2016;57(6):1251-3. doi: 10.3109/10428194.2016.1153090. Epub 2016 Mar 1. Leuk Lymphoma. 2016. PMID: 26926712 No abstract available.

3

Will we be able to afford a cure in multiple myeloma?

Chakraborty R, Gertz MA. Chakraborty R, et al. Leuk Lymphoma. 2018 Jan;59(1):1-2. doi: 10.1080/10428194.2017.1339883. Epub 2017 Jun 20. Leuk Lymphoma. 2018. PMID: 28629244 No abstract available.

4

Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population.

Chakraborty R, Rybicki L, Tomer J, Samaras CJ, Faiman BM, Valent J, Majhail NS. Chakraborty R, et al. Leuk Lymphoma. 2019 Dec;60(14):3544-3551. doi: 10.1080/10428194.2019.1623885. Epub 2019 Jul 5. Leuk Lymphoma. 2019. PMID: 31272258 Free PMC article.

5

Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.

Chakraborty R, Efficace F. Chakraborty R, et al. Br J Haematol. 2020 May;189(3):e112-e113. doi: 10.1111/bjh.16532. Epub 2020 Feb 20. Br J Haematol. 2020. PMID: 32080829 Free article. No abstract available.

6

Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.

Ball S, Behera TR, Anwer F, Chakraborty R. Ball S, et al. Among authors: chakraborty r. Ann Hematol. 2020 Jun;99(6):1265-1271. doi: 10.1007/s00277-020-04062-x. Epub 2020 May 7. Ann Hematol. 2020. PMID: 32382772

7

Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review.

Chakraborty R, Cannella L, Cottone F, Efficace F. Chakraborty R, et al. Lancet Haematol. 2020 Dec;7(12):e892-e901. doi: 10.1016/S2352-3026(20)30292-1. Lancet Haematol. 2020. PMID: 33242446

8

Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis.

Bhutani D, Pan S, Latif F, Goldsmith RL, Saith SE, Mapara MY, Chakraborty R, Lentzsch S, Maurer MS. Bhutani D, et al. Among authors: chakraborty r. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):545-548. doi: 10.1016/j.clml.2021.03.015. Epub 2021 Apr 23. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34024744

9

Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials.

Chakraborty R, Siddiqi R, Willson G, Gupta S, Asghar N, Husnain M, Aljama MA, Behera TR, Anwer F, Perrot A, Riaz IB. Chakraborty R, et al. Cancer. 2022 Jun 15;128(12):2288-2297. doi: 10.1002/cncr.34211. Epub 2022 Apr 4. Cancer. 2022. PMID: 35377484 Free article.

10

Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis.

Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R. Mian A, et al. Among authors: chakraborty r. Leuk Res. 2023 Aug;131:107324. doi: 10.1016/j.leukres.2023.107324. Epub 2023 May 23. Leuk Res. 2023. PMID: 37285641

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,498 results

Search Page